Performance
This page provides an overview of the performance of the Aescap Life Sciences and the Aescap Genetics fund. The historical NAVs of both funds can be found here.
- Net IRR since inception: from 4,5% – 23%.
- The fund outperforms the largest biotech ETF (IBB: iShares Biotech ETF).
- The significant decrease in performance during ’21/’22 was the result of the Covid-19 pandemic, when clinical trials where hampered, and are the engine of the biotech industry.
Net Performance Aescap Life Sciences as of 31-12-2025
- Launched in 2022.
- Aescap Genetics outperforms its benchmark, the J.P. Morgan Genetic Therapies Fund EUR.
